DOTCHIN & ASSOCIATES, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 Appropriations funding for Fiscal Year 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Defense DEF
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Health Issues HCR
S.4231 - Preparing for the Next Pandemic Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Alcohol and Drug Abuse ALC
CARA 3.0 - Comprehensive Addiction and Recovery Act Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT J. DOTCHIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.